Contact Us
Drug Search Results
More Filters [+]

Cyclophosphamide

Alternative Names: cyclophosphamide, cyclophosphamid, endoxan, cytoxan, cytophosphan, endoxana, ciclophosphamide, cyclophosphamides, ciclofosfamide, cytoxan (lyophilized), neosar, Sendoxan
Latest Update: 2025-01-28
Latest Update Note: Clinical Trial Update

Product Description

Cyclophosphamide is used to treat cancer of the ovaries, breast, blood and lymph system, and nerves (mainly in children). Cyclophosphamide is also used for retinoblastoma (a type of eye cancer mainly in children), multiple myeloma (cancer in the bone marrow), and mycosis fungoides (tumors on the skin). (Sourced from: https://www.mayoclinic.org/drugs-supplements/cyclophosphamide-oral-route-intravenous-route/description/drg-20063307)

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Breast Diseases | Hodgkin Lymphoma | Leukemia | Lymphoid Leukemia | Lymphoma | Multiple Myeloma | Mycosis Fungoides | Breast Cancer | Neuroblastoma | Retinoblastoma | Oncology Unspecified | Nephrotic Syndrome | Burkitt Lymphoma | Heart Failure | Myocarditis | Pericardial Effusion | Pulmonary Heart Disease | Alopecia | Breast Diseases | Liver Cirrhosis | Liver Failure | Febrile Neutropenia | Neutropenia | Hodgkin Lymphoma | Leukemia | Lymphoid Leukemia | Lymphoma | Multiple Myeloma | Mycosis Fungoides | Breast Cancer | Neuroblastoma | Pulmonary Blastoma | Retinoblastoma | Oncology Unspecified | Pregnancy Outcomes | Fetal Diseases | Nephrotic Syndrome | Pulmonary Fibrosis | Pulmonary Veno-Occlusive Disease | Respiratory Insufficiency | Diarrhea | Burkitt Lymphoma | Breast Diseases | Hodgkin Lymphoma | Leukemia | Lymphoid Leukemia | Lymphoma | Multiple Myeloma | Mycosis Fungoides | Adenocarcinoma | Breast Cancer | Neuroblastoma | Retinoblastoma | Oncology Unspecified | Burkitt Lymphoma

Known Adverse Events: Alopecia | Febrile Neutropenia | Neutropenia | Diarrhea | Kidney Diseases | Cardiac Arrhythmias | Heart Failure | Myocarditis | Pericardial Effusion | Pericarditis | Pulmonary Heart Disease | Liver Cirrhosis | Liver Failure | Contraception | Pulmonary Fibrosis | Pulmonary Veno-Occlusive Disease | Respiratory Insufficiency | Signs and Symptoms, Respiratory

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cyclophosphamide

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Uganda, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 139

Highest Development Phases

Phase 3: ANCA Vasculitis|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Amyloidosis|Breast Cancer|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Leukemia|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Multiple Myeloma|Multiple Sclerosis|Neuroblastoma|Neutropenia|Other|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Sarcoma|Sarcoma, Ewing|T-Cell Peripheral Lymphoma|Triple Negative Breast Cancer

Phase 2: B-Cell Marginal Zone Lymphoma|Biphenotypic Acute Leukemia|Bladder Cancer|Blood Protein Disorders|COVID-19|Colorectal Cancer|Digestive System Cancer|Epstein-Barr Virus Infections|Esophageal Cancer|Fallopian Tube Cancer|Fetal Diseases|Follicular Lymphoma|Gallbladder Cancer|Gastrointestinal Cancer|Glioma|Glomerulonephritis|Graft vs Host Disease|Head and Neck Cancer|Hepatocellular Carcinoma|Inflammatory Breast Cancer|Kidney Diseases|Kidney Transplant|Leukemia, Plasma Cell|Liposarcoma, Myxoid|Liver Cancer|Liver Transplant|Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma|Melanoma|Menopause|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic Syndrome|Non-Small-Cell Lung Cancer|Oncology Unspecified|Ovarian Cancer|Pancreatic Cancer|Paraproteinemias|Peritoneal Cancer|Plasmacytoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes|Primary Central Nervous System Lymphoma|Renal Transplant|Soft Tissue Cancer|Stem Cell Transplant|Stiff-Person Syndrome|Synovial Sarcoma|T-Cell Leukemia|T-Cell Lymphoma|Transitional Cell Carcinoma|Waldenstrom Macroglobulinemia

Phase 1: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Adenocarcinoma|Adrenocortical Carcinoma|Brain Stem Cancer|Central Nervous System Cancer|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Cutaneous Squamous Cell Carcinoma|Juvenile Myelomonocytic Leukemia,|Lung Cancer|Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic|Lupus Vasculitis|Male Breast Cancer|Medulloblastoma|Mesothelioma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Nose Cancer|Oncology Solid Tumor Unspecified|Oropharyngeal Cancer|Osteosarcoma|Papilloma|Paraganglioma|Pheochromocytoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Prostate Cancer|Relapsed/Refractory Lymphoma|Scleroderma, General|Skin Cancer|Small Cell Carcinoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Systemic Vasculitis|Thyroid Cancer|Uveal Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
TROPIKANA

P1

Recruiting

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Breast Cancer

2038-04-30

HR-NBL2

P3

Active, not recruiting

Neuroblastoma

2031-09-24

HEM-iSMART C

P2

Not yet recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin

2031-10-01

HEM-iSMART B

P2

Not yet recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin

2031-10-01

Recent News Events

Date

Type

Title

01/28/2025

News Article

 Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

01/24/2025

News Article

 Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

01/23/2025

News Article

 EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025

01/13/2025

News Article

 Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions